Liquid pharmaceutical formulations of tafamidis
US11980685B1 · kind B1 · utility
0Cited by
2References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2022 |
| Grant date | May 14, 2024 |
| Priority date | — |
| Expiry date | Dec 23, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/32
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Certain embodiments of the present disclosure provide liquid pharmaceutical formulations, suitable for oral administration, that contain an amount of a tafamidis of from 0.5 mg/ml to 20 mg/ml, water, and an amount of an alkaline pH modifier that yields a content of the tafamidis solubilized in the water of from 0.5 mg/ml to 19.8 mg/ml.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.